Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Nov 2;57(11):1193.
doi: 10.3390/medicina57111193.

Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Oliver Dulic  1   2   3   4   5 , Predrag Rasovic  2   3 , Ivica Lalic  2   3 , Vaso Kecojevic  2 , Gordan Gavrilovic  4 , Dzihan Abazovic  6 , Dusan Maric  3   5 , Mladen Miskulin  7   8 , Marko Bumbasirevic  1   9
Affiliations
Randomized Controlled Trial

Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Oliver Dulic et al. Medicina (Kaunas). .

Abstract

Background: In the last decade, regenerative therapies have become one of the leading disease modifying options for treatment of knee osteoarthritis (OA). Still, there is a lack of trials with a direct comparison of different biological treatments. Our aim was to directly compare clinical outcomes of knee injections of Bone Marrow Aspirate Concentrate (BMAC), Platelet-rich Plasma (PRP), or Hyaluronic acid (HA) in the OA treatment. Methods: Patients with knee pain and osteoarthritis KL grade II to IV were randomized to receive a BMAC, PRP, and HA injection in the knee. VAS, WOMAC, KOOS, and IKDC scores were used to establish baseline values at 1, 3, 6, 9, and 12 months. All side effects were reported. Results: A total of 175 patients with a knee osteoarthritis KL grade II-IV were randomized; 111 were treated with BMAC injection, 30 with HA injection, and 34 patients with PRP injection. There were no differences between these groups when considering KL grade, BMI, age, or gender. There were no serious side effects. The mean VAS scores after 3, 7, 14, and 21 days showed significant differences between groups with a drop of VAS in all groups but with a difference in the BMAC group in comparison to other groups (p < 0.001). There were high statistically significant differences between baseline scores and those after 12 months (p < 0.001) in WOMAC, KOOS, KOOS pain, and IKDC scores, and in addition, there were differences between these scores in the BMAC group in comparison with other groups, except for the PRP group in WOMAC and the partial IKDC score. There were no differences between the HA and PRP groups, although PRP showed a higher level of clinical improvement. Conclusions: Bone marrow aspirate concentrate, Leukocyte rich Platelet Rich Plasma, and Hyaluronic acid injections are safe therapeutic options for knee OA and provide positive clinical outcomes after 12 months in comparison with findings preceding the intervention. BMAC could be better in terms of clinical improvements in the treatment of knee OA than PRP and HA up to 12 months. PRP provides better outcomes than HA during the observation period, but these results are not statistically significant. More randomized controlled trials and high quality comparative studies are needed for direct correlative conclusions.

Keywords: bone marrow aspirate concentrate; hyaluronic acid; knee osteoarthritis; platelet rich plasma; regenerative medicine; stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study.
Figure 2
Figure 2
Visual Analog Scale pain before intervention and after 3, 7, 14, and 21 days.
Figure 3
Figure 3
KOOS overall scale before intervention and after 1, 3, 6, 9, and 12 months.
Figure 4
Figure 4
KOOS pain scale before intervention and after 1, 3, 6, 9, and 12 months.
Figure 5
Figure 5
WOMAC scale before intervention and after 1, 3, 6, 9, and 12 months.
Figure 6
Figure 6
IKDC scale before intervention and after 1, 3, 6, 9, and 12 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jones I.A., Togashi R., Wilson M.L., Heckmann N., Vangsness C.T., Jr. Intra-articular treatment options for knee osteoarthritis. Nat. Rev. Rheumatol. 2019;15:77–90. doi: 10.1038/s41584-018-0123-4. - DOI - PMC - PubMed
    1. Delanois R.E., Etcheson J.I., Sodhi N., Henn R.F., Gwam C.U., George N.E., Mont M.A. Biologic Therapies for the Treatment of Knee Osteoarthritis. J. Arthroplast. 2019;34:801–813. doi: 10.1016/j.arth.2018.12.001. - DOI - PubMed
    1. Connolly J.F., Guse R., Tiedeman J., Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin. Orthop. Relat. Res. 1991;266:259–270. doi: 10.1097/00003086-199105000-00038. - DOI - PubMed
    1. Kitaori T., Ito H., Schwarz E.M., Tsutsumi R., Yoshitomi H., Oishi S., Nakano M., Fujii N., Nagasawa T., Nakamura T. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009;60:813–823. doi: 10.1002/art.24330. - DOI - PubMed
    1. Masaki H., Ide H. Regeneration potency of mouse limbs. Dev. Growth Differ. 2007;49:89–98. doi: 10.1111/j.1440-169X.2007.00909.x. - DOI - PubMed

Publication types

Substances